Amgen’s portfolio is shifting toward faster-growing products like Repatha, EVENITY, and TEZSPIRE, but leverage and biosimilar erosion keep the stock in Hold territory. MariTide is the key medium-term catalyst, while Prolia and XGEVA remain the biggest drag.
Amgen (AMGN) offers a balanced medium-term investment case: a broad portfolio of marketed medicines, strong free cash flow, a growing group of newer products, and a late-stage pipeline led by MariTide. The main offset is a heavily leveraged balance sheet and accelerating biosimilar pressure on Prolia and XGEVA. At a quoted share price of $355.30, the stock is better suited to a patient holder than to an aggressive buyer.
The operating picture is improving. Q1 2026 revenue reached $8.62B, up 6% year over year, while non-GAAP EPS was $5.15, up 5%. Management reported that 16 products achieved double-digit growth and that 17 products were annualizing at more than $1B in sales. The six key growth drivers generated $5.6B in quarterly sales and grew 24% in aggregate.
The investment case depends on replacement. Repatha, EVENITY, TEZSPIRE, UPLIZNA, TEPEZZA, IMDELLTRA, and the biosimilar portfolio are growing quickly enough to offset the loss of exclusivity affecting older products. That transition is already visible in the sales data, but the debt load and the uncertain commercial payoff from MariTide keep the risk-reward profile from earning a stronger rating.
Amgen is a U.S.-based biotechnology company founded in 1980 and listed on the NASDAQ under AMGN. It had approximately 31,500 employees and a market capitalization of $209.2B. The company discovers, develops, manufactures, and commercializes human therapeutics worldwide.
Amgen operates as one human therapeutics segment, but its commercial portfolio spans general medicine, inflammation, bone health, cardiovascular disease, rare disease, oncology, and biosimilars. Principal products include Prolia, XGEVA, Repatha, Otezla, Enbrel, EVENITY, TEPEZZA, TEZSPIRE, UPLIZNA, BLINCYTO, IMDELLTRA, KRYSTEXXA, Nplate, and Vectibix.
Although Amgen reports one operating segment, its product groups have different growth and patent profiles. The 2025 mix shows a business moving away from reliance on older franchises. Enbrel revenue fell to $2.23B from $3.32B in 2024, while Repatha rose to $3.02B from $2.22B and EVENITY rose to $2.10B from $1.56B.
This mix is strategically healthier than a portfolio built around one blockbuster. It also creates a moving target for investors: fast-growing assets need to replace large but mature revenue streams before patent erosion overwhelms the newer products.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Repatha is Amgen's clearest flagship growth product. Full-year 2025 sales reached $3.02B, up 36%, and Q1 2026 sales rose 34% to $876M. Growth is supported by expanded use in secondary prevention and high-risk primary prevention, as well as updated ACC/AHA dyslipidemia guidelines that emphasize earlier risk identification and lower LDL-C targets.
The VESALIUS-CV program provides a significant clinical foundation. A prespecified subgroup analysis in high-risk patients with diabetes and without known significant atherosclerosis showed a 31% reduction in major adverse cardiovascular events. Repatha also showed nominal reductions of 32% in cardiovascular death and 24% in all-cause death in that subgroup.
Repatha's opportunity is not risk-free. Q1 product sales across Amgen rose 4% while volume increased 9%, with lower net selling price and lower inventory levels acting as offsets. The company has also introduced a simplified U.S. cash-pay option for Repatha. That action supports access, but it also confirms that pricing and reimbursement remain important parts of the commercial equation.
MariTide is the most important pipeline asset in the medium-term valuation. Amgen has initiated Phase III studies covering chronic weight management, maintenance therapy, and switching from weekly injectable therapies. Management describes a potential dosing schedule of monthly, every eight weeks, or quarterly administration.
MariTide's antibody-peptide conjugate design is intended to support sustained drug exposure and less frequent dosing. The program also uses three-step dose escalation after Amgen observed lower nausea and vomiting rates with earlier escalation approaches. The commercial opportunity is substantial, but Phase III execution and regulatory outcomes remain central to the investment case.
The rest of the pipeline adds depth. Olpasiran is in Phase III for secondary prevention of cardiovascular events and has delivered greater than 95% reduction in Lp(a) with quarterly dosing in earlier development. UPLIZNA has European Commission approval for generalized myasthenia gravis, while IMDELLTRA is being evaluated in earlier lines of small-cell lung cancer.
Amgen is also applying AI and human genetics to drug discovery, clinical trial site selection, regulatory preparation, and manufacturing. Management reported up to threefold improvement in enrollment rates in some clinical trial applications and a reduction in production line clearance time from approximately 30 minutes to about 2 minutes per batch run.
Amgen's manufacturing scale is a practical competitive advantage for biologics and biosimilars. The company operates manufacturing sites in Ohio, North Carolina, and Puerto Rico, and spent $712M on capital expenditures in Q1 2026. Management expects full-year 2026 capital expenditures of approximately $2.6B, including investment to scale capacity for volume growth and a potential MariTide launch.
The operating model remains highly profitable despite investment. Q1 2026 non-GAAP operating margin was 45%, while non-GAAP cost of sales was 19.5% of product sales. Higher profit-sharing and royalty expenses, along with product mix changes, are expected to pressure cost of sales in later quarters.
The supply-chain challenge is less about current production capacity than about matching capacity to portfolio change. Amgen is investing in manufacturing while Prolia and XGEVA face biosimilar erosion and newer products require additional supply. That makes the $2.6B capital expenditure plan strategically important, but it also raises execution demands.
Amgen participates in several large specialty pharmaceutical markets rather than one narrow category. Repatha addresses cardiovascular risk, EVENITY and Prolia address bone health, TEZSPIRE addresses severe asthma, TEPEZZA addresses thyroid eye disease, and MariTide targets obesity and related conditions.
The market backdrop favors therapies that improve outcomes in under-treated populations. Amgen reported that more than 90% of the 2 million U.S. women at very high fracture risk remain untreated, while its investor presentation cited approximately 100 million patients not at LDL-C goal. Those figures support the expansion opportunity for EVENITY and Repatha.
The counterweight is biologic pricing pressure. The FDA has said biologics account for 5% of prescriptions but 51% of drug spending, and the agency has approved 82 biosimilars. Amgen benefits from selling biosimilars, but it also faces direct erosion in products such as Prolia and XGEVA.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Amgen sells primarily through healthcare channels rather than directly to consumers. Its customers include physicians and clinics, hospitals, dialysis centers, pharmacies, and pharmaceutical wholesale distributors. Prescribing decisions depend on clinical evidence, payer coverage, reimbursement rules, and specialist adoption.
The strongest current customer traction is visible in specialist-led products. Repatha is gaining prescribing momentum among cardiologists and primary care physicians, EVENITY holds a 65% share of the U.S. bone-builder market, and IMDELLTRA is administered at more than 1,800 U.S. sites, with most doses delivered in community settings.
Access and convenience are becoming commercial differentiators. Amgen points to broad payer coverage for TEPEZZA, a cash-pay option for several products, and an on-body injector for TEPEZZA that produced comparable efficacy to intravenous administration in Phase III data. These features can expand treatment sites and reduce friction for patients and providers.
Amgen competes against different companies by product, not against one uniform peer group. Its 2025 annual report identifies AbbVie, Novartis, Sanofi and Regeneron, Pfizer, Bristol Myers Squibb, Merck, Roche, and Takeda Oncology among the competitors across its principal products.
Amgen's competitive strength is portfolio breadth combined with biologics expertise. The company has generated more than $14B in cumulative biosimilar sales since its first approvals in 2018, while its BiTE platform supports oncology products such as BLINCYTO and IMDELLTRA. That combination gives Amgen both a defense against biologic competition and a direct position in the lower-cost biologics market.
The primary competitive weakness is the maturity of several large franchises. Prolia and XGEVA together declined 32% in Q1 2026, and Enbrel declined from $3.32B in 2024 revenue to $2.23B in 2025. The newer portfolio must continue to scale faster than these legacy products contract.
Drug pricing policy and biosimilar adoption are the most direct macro forces for AMGN. Updated ACC/AHA lipid guidelines support earlier use of Repatha, while the FDA's biosimilar policy supports lower-cost competition. Those forces benefit Amgen's growth products and biosimilar business but pressure older biologic franchises at the same time.
Tax policy is another material external risk. Amgen is involved in tax court litigation covering 2010 through 2015 and received an April 2026 draft notice of proposed adjustment from the IRS covering 2016 through 2018. Management stated that the draft calculation, if sustained in full, could materially affect the company's financial statements.
The company is also directing capital toward domestic and regional manufacturing capacity. The planned $2.6B of 2026 capital expenditures and investments in Ohio, North Carolina, and Puerto Rico position the supply base for volume growth, but the spending increases the importance of disciplined capital allocation during a period of patent-driven revenue change.
Amgen’s balance sheet carries meaningful leverage, which keeps the C+ rating from matching the company’s improving operating momentum.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 revenue rose 6% to $8.62B and non-GAAP EPS increased 5% to $5.15, with six growth drivers contributing $5.6B and growing 24%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management’s 2026 outlook is supported by 16 double-digit growth products and 17 products already annualizing above $1B in sales.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At $355.30, Amgen trades just below our $360 fair value, leaving limited room for multiple expansion unless MariTide or the growth portfolio accelerates further.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework places AMGN’s fair value at $360, with the stock sitting between the Buy and Sell bands and landing on a Hold.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Amgen is executing the difficult middle act of a large biotech company's life cycle: mature products are losing exclusivity while newer medicines and pipeline programs must carry the business forward. Q1 2026 provided evidence that the transition is working, with $8.62B of revenue, 16 double-digit-growth products, and 24% growth across the six key growth drivers.
The strongest assets are Repatha, EVENITY, TEZSPIRE, UPLIZNA, TEPEZZA, IMDELLTRA, and the biosimilar portfolio. MariTide offers the largest potential step-up, while Olpasiran, UPLIZNA, IMDELLTRA, and the AI-enabled development platform add depth. The major risks are equally concrete: $54.60B of debt, $45.48B of net debt, Prolia and XGEVA erosion, and the IRS tax dispute.
The evidence supports a Hold for a medium-term, moderate-risk portfolio. AMGN has the cash flow and product breadth to compound through the transition, but the current valuation leaves limited room for operational disappointment. Better entry prices would improve the risk-reward balance without requiring investors to abandon the company's durable commercial and scientific strengths.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Amgen is growing through patent expirations with broad-based momentum across Repatha, rare disease, oncology, and biosimilars. The stock looks like a Buy, though valuation already reflects much of the resilience.
Amgen Inc. (AMGN) drops after reporting first-quarter 2026 results, even though the company beat Wall Street on earnings and revenue. Investors appear focused on valuation, growth quality, and whether the quarter was strong enough to justify the stock’s premium.
Prudential Financial, Inc. (PRU) gains after a strong earnings beat, but the deeper story is execution. EPS topped estimates by a wide margin, revenue edged past forecasts, and segment results, margin goals, and cost discipline show what could drive the next leg beyond this quarter.